The anti-TNF revolution in ankylosing spondylitis

Medical Journal of Australia

Volumn 181, Issue 10, 2004, Pages 529-530

  Schachna, Lionel ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL RESPONSE MODIFIER; CORTICOSTEROID; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; ANKYLOSIS; ASPERGILLOSIS; AUTOIMMUNE DISEASE; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; CRYPTOCOCCOSIS; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG TARGETING; EDITORIAL; ENTHESITIS; HUMAN; INFECTION RISK; LISTERIOSIS; LIVER DYSFUNCTION; MORTALITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PHYSIOTHERAPY; RHEUMATOID ARTHRITIS; SACROILIITIS; SIDE EFFECT; SPINE FUSION; SPINE MOBILITY; TUBERCULOSIS;

EID: 9144265513     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06436.x     Document Type: Editorial

References (11)

1. Health Insurance Commission. Pharmaceutical Benefits Scheme. Infliximab - for active ankylosing spondylitis. Schedule restriction details. 2004. Available at: www.hic.gov.au/providers/forms/pbs/mp/infliximab-as /schedule_restriction.htm (accessed Oct 2004).
2. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 174-176.
3. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42: 2325-2329.
4. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
5. van der Heijde D, Calin A, Dougados M, et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in ankylosing spondylitis. J Rheumatol 1999; 26: 951-954.
6. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-1886.
7. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-824.
8. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
9. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-2233.
10. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-3236.
11. Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63: 535-543.